SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
BOSTON, May 01, 2018 -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2018.
Participants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 6639039. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 7:30 p.m. ET on May 8, 2018 through May 15, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 6639039.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The company’s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:
Zafgen, Inc.
Patricia Allen
Chief Financial Officer
617-648-9792
Media
Krystle Gibbs
Ten Bridge Communications
[email protected]
508-479-6358
Investors
John Woolford
Westwicke Partners
[email protected]
443-213-0506
